Obesity Drug's Mid-Stage Win; Endocrine Disease Disparities; Chewing Away Diabetes?

An investigational dual glucagon/GLP-1 receptor agonist helped people with obesity or overweight, but without diabetes, shed about 15% of their body weight by 46 weeks in a phase II trial, Boehringer Ingelheim and Zealand Pharma announced.

As the World Health Organization conducts its first review of obesity management guidelines in over two decades, the organization's nutrition chief said that semaglutide (Wegovy) and other new weight-loss drugs are "no silver bullet" for global obesity. (Reuters)

The Endocrine Society released a new scientific statement on endocrine disease disparities in the pediatric population, as well as sexual and gender minority populations. (Journal of Clinical Endocrinology & Metabolism)

Closure of mesenteric defects during laparoscopic Roux-en-Y gastric bypass surgery cut the incidence of reoperation for small bowel obstruction from 14.9% to 7.8% during 10-year follow-up. (JAMA Surgery)

A single dose of 100-mg MDMA bolstered oxytocin concentrations in people with arginine vasopressin deficiency, formerly known as central diabetes insipidus. (The Lancet Diabetes & Endocrinology)

Families are struggling to find a growth hormone drug amid a persisting shortage. (NPR)

People with type 2 diabetes and diminished occlusal support were able to significantly reduce their HbA1c by chewing properly following an implant-supported fixed restoration. (PLOS One)

Treatment with a novel liver-selective thyroid hormone receptor beta agonist helped patients with biopsy-confirmed non-alcoholic steatohepatitis (NASH) achieve up to a 52% mean liver fat reduction by week 12 in a phase IIb trial, said Viking Therapeutics.

People with obesity who received GLP-1 receptor agonists had improved natural killer cell function, a small study suggested. (Obesity)

A bill to ban PFAS -- a class of endocrine-disrupting chemicals -- in household and industrial cleaning products is moving forward in California. (Environmental Working Group)

Comment